NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03568318,A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,https://clinicaltrials.gov/study/NCT03568318,AD Up,ACTIVE_NOT_RECRUITING,The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.,YES,Atopic Dermatitis,DRUG: Placebo|DRUG: Upadacitinib|DRUG: Topical corticosteroids (TCS),"Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 16|Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16, The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:

* 0 - Clear: No inflammatory signs of AD;
* 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification;
* 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting;
* 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present;
* 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present., Baseline and Week 16","Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores., Baseline (last available rolling average before the first dose of study drug) and Week 16|Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 16|Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores., Baseline (last available rolling average before the first dose of study drug) and Week 4|Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score., Baseline and Week 4|Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score., Baseline and Week 2|Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease., Baseline and Week 4|Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification.

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only., Baseline and Week 16|Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores., Baseline (last available rolling average before the first dose of study drug) and Week 1|Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement., Baseline (last available rolling average before the first dose of study drug) and Week 16|Main Study: Percent Change From Baseline in EASI Score at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement., Baseline and Week 16|Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score., Baseline and Week 16|Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16, The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:

* 0 - Clear: No signs of AD;
* 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification;
* 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting;
* 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting;
* 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting., Baseline and Week 16|Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores., Baseline (last available rolling average before the first dose of study drug) and Week 16|Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score., Baseline and Week 16|Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores., Baseline (last available rolling average before the first dose of study drug) and Week 4|Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score., Baseline and Week 4|Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score., Baseline and Week 2|Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score., Baseline and Week 4|Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16, EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification.

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.

The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only., Baseline and Week 16|Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores., Baseline (last available rolling average before the first dose of study drug) and Week 1|Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16, Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement., Baseline (last available rolling average before the first dose of study drug) and Week 16|Adolescents: Percent Change From Baseline in EASI Score at Week 16, EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema).

The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement., Baseline and Week 16",,AbbVie,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,968,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",M16-047|2017-005126-37,2018-08-09,2021-02-16,2030-11-16,2018-06-26,2022-02-07,2023-10-16,"Total Skin and Beauty Derm Ctr /ID# 200548, Birmingham, Alabama, 35205, United States|Clinical Research Center AL /ID# 201865, Birmingham, Alabama, 35209-6802, United States|ACCEL Research Sites /ID# 213364, Birmingham, Alabama, 35218, United States|Advanced Dermatology and Skin Care Centre /ID# 213550, Mobile, Alabama, 36605-3004, United States|Arizona Research Center, Inc. /ID# 200546, Phoenix, Arizona, 85053-4061, United States|Clear Dermatology & Aesthetics Center /ID# 201257, Scottsdale, Arizona, 85255-4134, United States|University of Arizona /ID# 201059, Tucson, Arizona, 85719, United States|Bakersfield Derma & Skin Cance /ID# 200892, Bakersfield, California, 93309, United States|Mosaic Dermatology /ID# 200553, Beverly Hills, California, 90211, United States|University of California Irvine /ID# 200902, Irvine, California, 92697-1385, United States|Therapeutics Clinical Research /ID# 200593, San Diego, California, 92123, United States|Stanford University /ID# 200597, Stanford, California, 94305, United States|Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822, Aurora, Colorado, 80045-2517, United States|Colorado Center for Dermatology, PLLC /ID# 203626, Centennial, Colorado, 80111-1724, United States|Duplicate_Western States Clinical Research, Inc. /ID# 201702, Wheat Ridge, Colorado, 80033-2896, United States|Dermatology Physicians of Connecticut /ID# 201004, Shelton, Connecticut, 06484-6211, United States|Clearlyderm Dermatology /ID# 207709, Boca Raton, Florida, 33428, United States|Skin Care Research, LLC /ID# 200812, Boca Raton, Florida, 33486-2269, United States|Clinical Research of West Florida, Inc /ID# 203643, Clearwater, Florida, 33765, United States|Florida Academic Centers Research and Education /ID# 200544, Coral Gables, Florida, 33134, United States|Tory P Sullivan, MD PA /ID# 201174, North Miami Beach, Florida, 33162-4708, United States|Park Avenue Dermatology, PA /ID# 201012, Orange Park, Florida, 32073, United States|Precision Clinical Research /ID# 208734, Sunrise, Florida, 33351-7311, United States|Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628, Boise, Idaho, 83713, United States|Northwestern University Feinberg School of Medicine /ID# 201646, Chicago, Illinois, 60611-2927, United States|Northshore University Health System Dermatology Clinical Trials Unit /ID# 200556, Skokie, Illinois, 60077, United States|DuPage Medical Group /ID# 202065, Wheaton, Illinois, 60189-3801, United States|Deaconess Clinic Downtown /ID# 201001, Evansville, Indiana, 47713-1227, United States|Indiana University /ID# 200515, Indianapolis, Indiana, 46202, United States|Epiphany Dermatology of Kansas LLC /ID# 203026, Overland Park, Kansas, 66210, United States|ORA, Inc. /ID# 202824, Andover, Massachusetts, 01810, United States|Tufts Medical Center /ID# 200570, Boston, Massachusetts, 02111-1552, United States|Beth Israel Deaconess Medical Center /ID# 200545, Boston, Massachusetts, 02215-5400, United States|Clin Res Inst of Michigan, LLC /ID# 208020, Chesterfield, Michigan, 48047, United States|Michigan Center for Research Company /ID# 200560, Clarkston, Michigan, 48346, United States|MediSearch Clinical Trials /ID# 201006, Saint Joseph, Missouri, 64506, United States|Skin Specialists, PC /ID# 200573, Omaha, Nebraska, 68144, United States|Dartmouth-Hitchcock Medical Center /ID# 200918, Lebanon, New Hampshire, 03756, United States|Psoriasis Treatment Center of Central New Jersey /ID# 200714, East Windsor, New Jersey, 08520, United States|Juva Skin and Laser Center /ID# 200997, New York, New York, 10022-3204, United States|J. Schwartz, MD, PLLC /ID# 202122, Troy, New York, 12180-2323, United States|Bexley Dermatology Research /ID# 200899, Bexley, Ohio, 43209-2422, United States|The Ohio State University /ID# 200542, Columbus, Ohio, 43210-1257, United States|Vital Prospects Clinical Research Institute, PC /ID# 200901, Tulsa, Oklahoma, 74136-7049, United States|Oregon Dermatology and Research Center /ID# 200601, Portland, Oregon, 97210, United States|University of Pittsburgh MC /ID# 206057, Pittsburgh, Pennsylvania, 15260, United States|Rhode Island Hospital /ID# 200566, Providence, Rhode Island, 02903, United States|AAPRI Clinical Research /ID# 221134, Warwick, Rhode Island, 02886-2876, United States|Rivergate Dermatology & Skin Care Center /ID# 201698, Goodlettsville, Tennessee, 37072-2301, United States|Stones River Dermatology /ID# 204962, Murfreesboro, Tennessee, 37129-3194, United States|Arlington Research Center, Inc /ID# 200559, Arlington, Texas, 76011, United States|Center for Clinical Studies /ID# 200582, Houston, Texas, 77004, United States|Progressive Clinical Research /ID# 201582, San Antonio, Texas, 78229, United States|Center for Clinical Studies - Webster TX /ID# 203186, Webster, Texas, 77598, United States|Advanced Clinical Research - Woseth Dermatology /ID# 213745, Salt Lake City, Utah, 84117-4209, United States|Eastern Virginia Med School /ID# 200994, Norfolk, Virginia, 23507-1627, United States|Dermatology Associates of Seattle /ID# 200717, Seattle, Washington, 98101, United States|University of Wisconsin - Madison /ID# 204933, Madison, Wisconsin, 53715-1218, United States|St George Dermatology & Skin Cancer Centre /ID# 204788, Kogarah, New South Wales, 2217, Australia|Royal North Shore Hospital /ID# 204639, St Leonards, New South Wales, 2065, Australia|Westmead Hospital /ID# 205682, Westmead, New South Wales, 2145, Australia|Veracity Clinical Research /ID# 204793, Woolloongabba, Queensland, 4102, Australia|Fremantle Dermatology /ID# 205306, Fremantle, Western Australia, 6160, Australia|Ordensklinikum Linz GmbH Elisabethinen /ID# 209567, Linz, Oberoesterreich, 4010, Austria|Kepler Universitaetsklinikum GmbH /ID# 201075, Linz, Oberoesterreich, 4021, Austria|Medizinische Universitaet Innsbruck /ID# 210897, Innsbruck, Tirol, 6020, Austria|Medizinische Universitaet Wien /ID# 201080, Vienna, Wien, 1090, Austria|UZ Brussel /ID# 203557, Jette, Bruxelles-Capitale, 1090, Belgium|UCL Saint-Luc /ID# 202028, Woluwe-Saint-Lambert, Bruxelles-Capitale, 1200, Belgium|UZ Gent /ID# 202030, Gent, Oost-Vlaanderen, 9000, Belgium|IMTR - Grand Hopital de Charleroi /ID# 202029, Loverval, 6280, Belgium|Kirk Barber Research, CA /ID# 200329, Calgary, Alberta, T2G 1B1, Canada|Dermatology Research Institute Inc. /ID# 200341, Calgary, Alberta, T2J 7E1, Canada|Alberta DermaSurgery Centre /ID# 205674, Edmonton, Alberta, T6G 1C3, Canada|Karma Clinical Trials /ID# 200339, St. John's, Newfoundland and Labrador, A1A 4Y3, Canada|Eastern Canada Cutaneous Resea /ID# 200335, Halifax, Nova Scotia, B3H 1Z2, Canada|Lynderm Research Inc. /ID# 200338, Markham, Ontario, L3P 1X2, Canada|DermEdge Research Inc. /ID# 200337, Mississauga, Ontario, L5H 1G9, Canada|The Centre for Clinical Trials /ID# 205404, Oakville, Ontario, L6J 7W5, Canada|Angela Montgomery Medicine Professional Corporation /ID# 212653, Ottawa, Ontario, K1H 7X3, Canada|SKIN Centre for Dermatology /ID# 200331, Peterborough, Ontario, K9J 5K2, Canada|The Center For Dermatology /ID# 205409, Richmond Hill, Ontario, L4B 1A5, Canada|Toronto Research Centre /ID# 205411, Toronto, Ontario, M3H 5Y8, Canada|Research Toronto /ID# 205410, Toronto, Ontario, M4W 2N4, Canada|XLR8 Medical Research /ID# 205405, Windsor, Ontario, N8W 1E6, Canada|CHU Sainte-Justine /ID# 206013, Montreal, Quebec, H3T 1C5, Canada|Centre de recheche dermatologique du Quebec Metropolitain /ID# 205403, Québec, Quebec, G1V 4X7, Canada|Dre Angelique Gagne-Henley M.D. inc. /ID# 200330, Saint-Jerome, Quebec, J7Z 7E2, Canada|Chinese PLA General Hospital /ID# 206786, Beijing, Beijing, 100853, China|Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 206728, Guangzhou, Guangdong, 510120, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 206669, Wuhan, Hubei, 430022, China|The First Hospital of China Medical University /ID# 209840, Shenyang, Liaoning, 110001, China|The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 207132, Hangzhou, Zhejiang, 310006, China|The second Affiliated hospital of Zhejiang University school of Medicine /ID# 207442, Hangzhou, Zhejiang, 310009, China|Beijing Friendship Hospital /ID# 207434, Beijing, 100032, China|Xiangya Hospital Central South University /ID# 207510, Changsha, 410008, China|Huashan Hospital of Fudan University /ID# 207437, Shanghai, 200040, China|Fakultni nemocnice Plzen /ID# 202044, Plzen, 305 99, Czechia|Duplicate_Vseobecna Fakultni Nemocnice /ID# 205248, Prague, 128 08, Czechia|Sanatorium profesora Arenbergera /ID# 202082, Praha, 110 00, Czechia|Vseobecna fakultni nemocnice v Praze /ID# 202045, Praha, 128 08, Czechia|Chu de Nice-Hopital L'Archet Ii /Id# 205780, Nice, Alpes-Maritimes, 06200, France|AP-HM - Hopital de la Timone /ID# 206128, Marseille CEDEX 05, Bouches-du-Rhone, 13385, France|CHRU Tours - Hopital Gatien de Clocheville /ID# 218209, Tours, Centre-Val De Loire, 37044, France|Hopital Saint-Andre /ID# 206129, Bordeaux, 33075, France|Polyclinique Courlancy /ID# 201537, Reims, 51100, France|Universitaetsklinik Heidelberg /ID# 202097, Heidelberg, Baden-Wuerttemberg, 69120, Germany|Universitaetsklinikum Frankfurt /ID# 202095, Frankfurt am Main, Hessen, 60590, Germany|Universitaetsklinikum Muenster /ID# 202094, Muenster, Nordrhein-Westfalen, 48149, Germany|CMS3 Company for Medical Study /ID# 205195, Selters, Rheinland-Pfalz, 56242, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202256, Kiel, Schleswig-Holstein, 24105, Germany|Universitaetsklinikum Bonn /ID# 202092, Bonn, 53127, Germany|TFS Trial Form Support GmbH /ID# 202096, Hamburg, 20537, Germany|Medizinische Hochschule Hannover /ID# 202098, Hannover, 30625, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205194, Mainz, 55131, Germany|Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202093, Munich, 81675, Germany|401 GSNA - 401 Army General Hospital /ID# 211963, Athens, Attiki, 11525, Greece|Children's Hosp P. A. Kyriakou /ID# 217573, Athens, Attiki, 11527, Greece|University General Hospital Attikon /ID# 201126, Athens, Attiki, 12462, Greece|General Hospital Andreas Syggros /ID# 201123, Athens, Attiki, 16121, Greece|Papageorgiou General Hospital Thessaloniki /ID# 202392, Stavroupoli (Thessalonikis), Thessaloniki, 55536, Greece|Thessaloniki Hospital of Skin and Venereal Diseases /ID# 201124, Thessaloniki, 54643, Greece|Prince of Wales Hospital /ID# 205152, Hong Kong, 999077, Hong Kong|Queen Mary Hospital /ID# 205146, Hong Kong, 999077, Hong Kong|Oroshazi Korhaz /ID# 203525, Oroshaza, Bekes, 5900, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 204144, Szeged, Csongrad, 6725, Hungary|Debreceni Egyetem Klinikai Kozpont /ID# 201765, Debrecen, Hajdu-Bihar, 4032, Hungary|Derma-B Egeszsegugyi es Szolgaltato Kft. /ID# 217866, Debrecen, 4031, Hungary|Allergo-Derm Bakos Kft. /ID# 205361, Szolnok, 5000, Hungary|St James Hospital /ID# 201118, Dublin 8, Dublin, D08 NHY1, Ireland|South Infirmary Victoria University Hospital /ID# 201079, Cork, T12 X23H, Ireland|University Hospital Waterford /ID# 201253, Waterford, X91 ER8E, Ireland|Soroka University Medical Center /ID# 206652, Be'er Sheva, HaDarom, 8443901, Israel|The Chaim Sheba Medical Center /ID# 201611, Ramat Gan, Tel-Aviv, 5265601, Israel|Tel Aviv Sourasky Medical Center /ID# 201608, Tel Aviv-Yafo, Tel-Aviv, 6423906, Israel|HaEmek Medical Center /ID# 201958, Afula, 1834111, Israel|Rabin Medical Center /ID# 201959, Petakh Tikva, 4941492, Israel|Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 203014, Rome, Lazio, 00168, Italy|Istituto Clinico Humanitas /ID# 200739, Rozzano, Milano, 20089, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200690, Ancona, 60126, Italy|A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200742, Catania, 95123, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 200744, Milan, 20122, Italy|Azienda Ospedaliera Universitaria Federico II /ID# 200751, Napoli, 80131, Italy|Chukyo Hospital /ID# 202311, Nagoya-shi, Aichi, 457-8510, Japan|Medical Corporation Matsuo Clinic /ID# 202312, Fukuoka-shi, Fukuoka, 819-0373, Japan|Hiroshima University Hospital /ID# 201914, Hiroshima-shi, Hiroshima, 734-8551, Japan|Hiramoto skin clinic /ID# 204048, Amagasaki-shi, Hyogo, 661-0953, Japan|National Hospital Organization Sagamihara National Hospital /ID# 201658, Sagamihara-shi, Kanagawa, 252-0392, Japan|Queens Square Medical Center dermatology allergology /ID# 203850, Yokohama-shi, Kanagawa, 220-6208, Japan|Kyoto University Hospital /ID# 201654, Kyoto-shi, Kyoto, 606-8507, Japan|Tohoku University Hospital /ID# 206322, Sendai-shi, Miyagi, 9808574, Japan|Osaka Habikino Medical Center /ID# 204243, Habikino-shi, Osaka, 583-8588, Japan|Jichi Medical University Hospital /ID# 201913, Shimotsuke-shi, Tochigi, 329-0498, Japan|Juntendo University Hospital /ID# 202888, Bunkyo-ku, Tokyo, 113-8431, Japan|Tokai University Hachioji Hospital /ID# 201711, Hachioji-shi, Tokyo, 192-0032, Japan|Maruyama Dermatology Clinic /ID# 202350, Koto-ku, Tokyo, 136-0074, Japan|Yamate Dermatological Clinic /ID# 202130, Shinjuku-ku, Tokyo, 1690075, Japan|Erasmus Medisch Centrum /ID# 202196, Rotterdam, Zuid-Holland, 3015 GD, Netherlands|Academisch Medisch Centrum /ID# 202193, Amsterdam, 1105 AZ, Netherlands|Universitair Medisch Centrum Groningen /ID# 202195, Groningen, 9713 GZ, Netherlands|Universitair Medisch Centrum Utrecht /ID# 202194, Utrecht, 3584 CX, Netherlands|Clinical Trials NZ /ID# 205336, Hamilton, 3204, New Zealand|Haukeland University Hospital /ID# 201152, Bergen, Hordaland, 5021, Norway|Universitetssykehuset N-Norge, Harstad /ID# 201269, Harstad, Troms, 9406, Norway|Universitetssykehuset N-Norge, Tromso /ID# 201270, Tromso, Troms, 9019, Norway|Rikshospitalet OUS HF /ID# 201271, Oslo, 0450, Norway|Dr. Samuel Sanchez PSC /ID# 202002, Caguas, 00727, Puerto Rico|Clinical Research Puerto Rico /ID# 203644, San Juan, 00909, Puerto Rico|GCM Medical Group PSC - Hato Rey /ID# 202003, San Juan, 00917-3104, Puerto Rico|Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 204372, Banska Bystrica, 975 17, Slovakia|Univerzitna nemocnica Martin /ID# 203851, Martin, 036 01, Slovakia|Fakultna nemocnica s poliklinikou Nove Zamky /ID# 204240, Nove Zamky, 940 34, Slovakia|Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 204373, Presov, 081 01, Slovakia|Hospital Universitario de Puerto Real /ID# 200875, Puerto Real, Cadiz, 11510, Spain|Hospital General Universitario Alicante /ID# 200873, Alicante, 03010, Spain|Hospital Santa Creu i Sant Pau /ID# 201325, Barcelona, 08041, Spain|Hospital Universitario de la Princesa /ID# 201517, Madrid, 28006, Spain|Hospital Universitario 12 de Octubre /ID# 201135, Madrid, 28041, Spain|Hospital Universitario La Paz /ID# 205438, Madrid, 28046, Spain|Skane University Hospital Lund /ID# 201244, Lund, Skane Lan, SE 221 41, Sweden|Sahlgrenska University Hospital /ID# 201274, Gothenburg, Vastra Gotalands Lan, 413 46, Sweden|Sodersjukhuset /ID# 201242, Stockholm, 118 83, Sweden|Karolinska University Hospital /ID# 201243, Stockholm, 171 76, Sweden|Barts Health NHS Trust /ID# 201044, London, London, City Of, E1 2ES, United Kingdom|Guy's and St Thomas' NHS Foundation Trust /ID# 201193, London, London, City Of, SE1 9RT, United Kingdom|Guy's and St Thomas' NHS Foundation Trust /ID# 204642, London, London, City Of, SE1 9RT, United Kingdom|Oxford University Hospitals NHS Foundation Trust /ID# 202052, Oxford, Oxfordshire, OX3 9DU, United Kingdom|NHS Tayside /ID# 202081, Dundee, Scotland, DD2 1UB, United Kingdom|NHS Greater Glasgow and Clyde /ID# 201374, Glasgow, Scotland, G12 0XH, United Kingdom|Leeds Teaching Hospitals NHS Trust /ID# 201106, Leeds, LS9 7TF, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/18/NCT03568318/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/18/NCT03568318/SAP_001.pdf"
